AstraZeneca says Covid-19 vaccine trial in U.S still on hold
AstraZeneca Plc said the company’s Covid-19 vaccine trial in the United States is still on hold.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain
/in Analysts, Blockbusters, Brain, Business, Clinical Trials, EGFR Mutations, European Society for Medical Oncology (ESMO), Lung Cancer, Lung Tumors, R&D, TherapeuticsFRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumor to be surgically removed, and who have a […]
Immunomedics drug Trodelvy extends survival in breast cancer patients
/in Accelerated Approval, Antibody-Drug Conjugates (ADCs), Boxed Warning, Business, Cancer Cells, Clinical Trials, Deals, European Society for Medical Oncology (ESMO), FDA, Metastatic Triple-Negative Breast Cancer (mTNBC), R&D, TherapeuticsImmunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.
Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study
/in Analysts, Blockbusters, Clinical Data, Clinical Trials, Combination Therapies, European Society for Medical Oncology (ESMO), Immunotherapies, Kidney Cancer, Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), Researchers, TherapeuticsBristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on […]
Regeneron and Sanofi’s Checkpoint Inhibitor Shines in Phase II BCC Study
/in Basal Cell Carcinoma, Business, Checkpoint Inhibitors, Clinical Data, Clinical Trials, European Society for Medical Oncology (ESMO), Hedgehog Pathway Inhibitors, Partnerships, PD-1 Inhibitors, R&DRegeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
T cell shortage linked to severe Covid-19 in elderly; antiseptic spray may limit virus spread
/in Antibodies, Antiseptics, COVID-19 Antibodies, Doctors, Elderly, Immune Response, Immunoglobulin G (IgG), Infected Cells, Infected Cells, Inflammation, JAMA Otolaryngology Head and Neck Surgery, R&D, Scientists, Severe Covid-19, Studies, T-CellsA lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More
/in Advanced Melanoma, Advanced Squamous Carcinoma of the Anal Canal (SCAC), Biomarkers, Blockbusters, Clinical Data, Clinical Trials, Epstein-Barr Virus, European Society for Medical Oncology (ESMO), Lung Cancer, Ovarian Cancer, PD-1/PD-L1 inhibitors, Platinum-Based Chemotherapy, R&D, TherapeuticsAstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Genentech Drug Benefits Patients with Covid-19-Associated Pneumonia, Study Shows
/in Blockbusters, Clinical Data, Clinical Trials, Covid-19 Pneumonia, Ethnicity, Hospitalized patients, Interleukin-6 (IL-6), Minorities, R&D, Racial Groups, Rheumatoid Arthritis, Secondary Endpoints, TherapeuticsA rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.
Moderna expects to make 20 million doses of Covid-19 vaccine candidate by 2020 end
/in Clinical Trials, Coronavirus Vaccines, Emergency Use Authorization, FDA, FDA/Regulatory, Moderna, R&D, U.S. Centers for Disease Control and PreventionModerna Inc. expects to produce 20 million doses of the company’s experimental coronavirus vaccine by the end of 2020.
EU regulator backs dexamethasone as Covid-19 treatment
/in Adolescents, Adults, Coronavirus, Dexamethasone, Europe, European Medicines Agency, FDA/Regulatory, Japan, Oxford University, Respiratory Illnesses, SteroidsEurope’s healthcare regulator endorsed using dexamethasone to treat Covid-19 patients with breathing difficulties, paving the way for the steroid to become the region’s second approved treatment for the respiratory illness.
